Comparison of Letrozole versus Danazol for the Pain Management of Females Presented with Endometriosis

In: Annals of King Edward Medical University · 2018 · vol. 23(4) , pp. 514–518 · doi:10.21649/akemu.v23i4.2231 · W2796108889
article OA: diamond CC0 ⤵ 3 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-11

This study found that danazol treatment resulted in a greater decrease in visual analogue scale pain scores compared to letrozole treatment in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-11 · read from full text

This study compared letrozole versus danazol for pelvic pain management in 140 females diagnosed with endometriosis via diagnostic laparoscopy, using purposive non-probability sampling and measuring pain with visual analogue scale (VAS) scores over 3 months. Patients received letrozole 2.5 mg/day (group A) or danazol 600 mg/day (group B), and the primary outcome was the mean decrease in VAS pain score analyzed with an independent-samples t-test. After treatment, mean VAS pain scores were 2.01±0.95 in the letrozole group and 2.78±0.99 in the danazol group, with a reported greater mean pain-score decrease for danazol (3.06±1.23) than letrozole (1.02±1.09), both with p-values reported as 0.00. This paper is centrally about endometriosis — it directly compares letrozole versus danazol for reducing endometriosis-associated pelvic pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is an estrogen-regulated disease, and is signified by the existence of a particular endometrial tissue exterior to the uterus. It is a principal cause of long lasting morbidity, mostly from serious pelvic pain(1). Endometriotic tissue has the potential for aromatase gene expression that leads to aromataseand estrogen production. Danazol is a synthetic androgen whereas Letrozole is aromatase inhibitor. This study was conducted to compare the mean decrease in visual analogue scale (VAS) pain score with Danazol versus Letrozole for the pain management of endometriosis in females. A total of 140 females fulfillinginclusion criteria were registered and an non-probability purposive technique of sampling was used. Diagnostic laparoscopy was conducted to make a diagnosis of endometriosis. Females were divided into two groups. Females in group A received treatment with Letrozole tablets (2.5 mg/day) and in group B receivedDanazol tablets (600 mg/day) for 3 months. Pelvic pain was assessed using VAS score and the mean decrease in pain score was assessed between two groups using independent sample student t-test. Results of this study demonstrate that the mean age of the patients was 29.99±5.80 and the mean pain score before treatment in Letrozole group was 3.04±1.01 while in Danazol group was 5.05±1.02. Post-three months of treatments, mean pain score was 2.01±0.95 and 2.78±0.99 in Letrozole and Danazol groups, respectively. The mean decrease in pain score in Letrozole group was 1.02±1.09 (p-value=0.00) while in Danazol group; it was 3.06±1.23 (p-value=0.00). This difference in pain score was considerably different in both treatment groups. A higher decrease in pain score was observed in Danazol compared to Letrozole treated groups.
Full text 2,354 characters · extracted from oa-doi-fallback · click to expand
Comparison of Letrozole versus Danazol for the Pain Management of Females Presented with Endometriosis DOI: https://doi.org/10.21649/akemu.v23i4.2231Keywords: Danazol, Letrozole, Pelvic pain, EndometriosisAbstract Endometriosis is an estrogen-regulated disease, and is signified by the existence of a particular endometrial tissue exterior to the uterus. It is a principal cause of long lasting morbidity, mostly from serious pelvic pain(1). Endometriotic tissue has the potential for aromatase gene expression that leads to aromatase and estrogen production. Danazol is a synthetic androgen whereas Letrozole is aromatase inhibitor. This study was conducted to compare the mean decrease in visual analogue scale (VAS) pain score with Danazol versus Letrozole for the pain management of endometriosis in females. A total of 140 females fulfilling inclusion criteria were registered and an non-probability purposive technique of sampling was used. Diagnostic laparoscopy was conducted to make a diagnosis of endometriosis. Females were divided into two groups. Females in group A received treatment with Letrozole tablets (2.5 mg/day) and in group B received Danazol tablets (600 mg/day) for 3 months. Pelvic pain was assessed using VAS score and the mean decrease in pain score was assessed between two groups using independent sample student t-test. Results of this study demonstrate that the mean age of the patients was 29.99±5.80 and the mean pain score before treatment in Letrozole group was 3.04±1.01 while in Danazol group was 5.05±1.02. Post-three months of treatments, mean pain score was 2.01±0.95 and 2.78±0.99 in Letrozole and Danazol groups, respectively. The mean decrease in pain score in Letrozole group was 1.02±1.09 (p-value=0.00) while in Danazol group; it was 3.06±1.23 (p-value=0.00). This difference in pain score was considerably different in both treatment groups. A higher decrease in pain score was observed in Danazol compared to Letrozole treated groups. Downloads Published How to Cite Issue Section License This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments [email protected]

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

VAS-pain

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK